High affinity human antibodies to human IL-4 receptor
An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with high affinity (K D ), capable of blocking hIL-4 and hIL-13 activity.
1. An isolated antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 274, comprising a heavy chain variable region comprising three heavy-chain CDRs, and a light chain variable region comprising three light-chain CDRs, wherein said three heavy-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:162, and said three light-chain CDRs comprise the CDR1, CDR2 and CDR3 from SEQ ID NO:164.
2. The antibody or antigen-binding fragment of claim 1 , wherein said heavy chain CDR1 comprises SEQ ID NO:148, said heavy chain CDR2 comprises SEQ ID NO:150, said heavy chain CDR3 comprises SEQ ID NO:152, said light chain CDR1 comprises SEQ ID NO:156, said light chain CDR2 comprises SEQ ID NO:158, and said light chain CDR3 comprises SEQ ID NO:160.
3. The antibody or antigen-binding fragment of claim 2 , wherein said heavy chain variable region comprises SEQ ID NO:162.
4. The antibody or antigen-binding fragment of claim 2 , wherein said light chain variable region comprises SEQ ID NO:164.
5. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 1 and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 , wherein said heavy chain CDR1 comprises SEQ ID NO:148, said heavy chain CDR2 comprises SEQ ID NO:150, said heavy chain CDR3 comprises SEQ ID NO:152, said light chain CDR1 comprises SEQ ID NO:156, said light chain CDR2 comprises SEQ ID NO:158, and said light chain CDR3 comprises SEQ ID NO:160.
7. The pharmaceutical composition of claim 6 , wherein said heavy chain variable region comprises SEQ ID NO:162.
8. The pharmaceutical composition of claim 6 , wherein said light chain variable region comprises SEQ ID NO:164.
9. An antibody or antigen-binding fragment thereof, which specifically binds human interleukin-4 receptor (hIL-4R) comprising the amino acid sequence of SEQ ID NO: 274, comprising a heavy chain variable region comprising SEQ ID NO:162 and a light variable region comprising SEQ ID NO:164.
10. A pharmaceutical composition comprising the antibody or antigen-binding fragment of claim 9 and a pharmaceutically acceptable carrier.